Publications

Nature

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-09-2022

Key

Molecular cell

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

18-11-2021

Key

Nature genetics

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.

01-01-2021

Key

British journal of cancer

Ductal carcinoma in situ: to treat or not to treat, that is the question.

01-08-2019

Key

Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019

Key

Nature cell biology

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

01-04-2019

Key

Genes & development

BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.

07-11-2024

Nature

Mechanisms that clear mutations drive field cancerization in mammary tissue.

01-09-2024

The Journal of pathology

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

01-07-2024

Journal of mammary gland biology and neoplasia

Transcriptomic Analysis of Pubertal and Adult Virgin Mouse Mammary Epithelial and Stromal Cell Populations.

25-06-2024

Journal of mammary gland biology and neoplasia

Rat Models of Hormone Receptor-Positive Breast Cancer.

24-06-2024

Nature communications

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.

24-05-2024

The EMBO journal

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

01-03-2024

Breast cancer research : BCR

Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.

19-02-2024

EMBO molecular medicine

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

07-12-2023

The Journal of experimental medicine

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

06-11-2023

Journal of mammary gland biology and neoplasia

Fourteenth Annual ENBDC Workshop: Methods in Mammary Gland Biology and Breast Cancer.

06-10-2023

STAR protocols

Mouse intraductal modeling of primary ductal carcinoma in situ.

15-09-2023

Molecular cell

Genome-scale mapping of DNA damage suppressors through phenotypic CRISPR-Cas9 screens.

03-08-2023

Clinical and translational medicine

MIND the translational gap: Preclinical models of ductal carcinoma in situ.

01-08-2023

Journal of mammary gland biology and neoplasia

Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research.

14-07-2023

Science advances

FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks.

02-06-2023

Cell reports

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

30-05-2023

Cancer cell

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

08-05-2023

Nature communications

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

07-04-2023

Nature reviews. Cancer

Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-02-2023

Nature communications

CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer.

12-01-2023

Nature reviews. Cancer

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-12-2022

Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022

Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-08-2022

Cancers

Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases.

25-06-2022

Breast cancer research : BCR

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

17-06-2022

Molecular & cellular oncology

Filling in the gaps in PARP inhibitor-induced synthetic lethality.

15-04-2022

STAR protocols

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids.

18-03-2022

Cancer research

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture.

01-02-2022

Cancer research

A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.

15-12-2021

Nature reviews. Clinical oncology

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

01-12-2021

Cancers

Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

27-10-2021

Molecular cell

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.

05-08-2021

Cancers

PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.

18-07-2021

Nature communications

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

16-07-2021

Nature genetics

Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.

01-05-2021

Science advances

SMARCAD1-mediated active replication fork stability maintains genome integrity.

01-05-2021

Molecular & cellular proteomics : MCP

Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate.

06-04-2021

Cancers

Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.

22-03-2021

Current opinion in genetics & development

The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice.

01-02-2021

Annals of oncology : official journal of the European Society for Medical Oncology

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

01-12-2020

Nat. Commun: Nature Communications

Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

30-11-2020

Nat. Commun: Nature Communications

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

21-09-2020

Current biology : CB

How the COVID-19 pandemic highlights the necessity of animal research.

21-09-2020